lilly oral glp-1 Orforglipron Is Approved for Obesity FDA approves new weight-loss pill,

Glutationa antioxidante

Kastenmller received funding (through their institutions) from the National Institutes of Health/National Institute on Aging through grants RF1AG058942, RF1AG059093, U01AG061359, U19AG063744, R01AG069901, and R01AG081322

This was the first approval of a weight-loss medication specifically for cardiovascular risk reduction, further strengthening the clinical value proposition of GLP-1 therapies In December 2024, the U.S

Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction